The present study was designed to establish if Etodolac, a selective cyclooxygenase-2 inhibitor, prevents chemically induced intraductal papillary carcinoma (IPC) in the main pancreatic duct of hamsters. Hamsters were subjected to cholecystoduodenostomy with dissection of the distal end of the common duct. Four weeks after surgery, the surviving hamsters were given subcutaneous injections of N-nitrosobis(2-oxopropyl)amine (BOP) 10 mg/kg body weight, every 2 weeks, four times. The animals were divided into three groups based on the simultaneous oral intake of a CE-2 pelleted diet, which contained 0% (group CE, n = 30), 0.01% (group ET, n = 21), or 0.04% Etodolac (group ET4, n = 25), respectively. Hamsters were killed for pathological examination 36 weeks after the operation. The incidence of induced pancreatic carcinoma was 93%, 81%, and 72% in groups CE, ET, and ET4, respectively. The pancreatic carcinomas were classified into four histological types: tubular, papillary, and cystic adenocarcinoma, and IPC. The incidence of IPC and the number of IPCs per animal were significantly lower in groups ET4 (36% and 0.48) and ET (48% and 0.62) than in group CE (67% and 1.30). The proliferating cell nuclear antigen labeling indices in the noncancerous epithelial cells of the main pancreatic duct were 2.8% and 6.8% in groups ET4 and ET, respectively; being significantly lower than that in group CE (10.8%). In conclusion, Etodolac inhibited BOP-induced IPC in hamsters. The suppression of epithelial cell proliferation of the main pancreatic duct was considered a possible mechanism of cancer prevention in this hamster model.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hruban R.H., Takaori K., Klimstra D.S., Adsay N.V., Albores-Saavedra J., Biankin A.V., Biankin S.A., Compton C., Fukushima N., Furukawa T., Goggins M., Kato Y., Kloppel G., Longnecker D.S., Luttges J., Maitra A., Offerhaus G.J., Shimizu M., Yonezawa S. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol., 2004 28:977–987.
Ohhashi K., Murakami Y., Maruyama M., Takekoshi T., Ohta H., Ohhashi I., Takagi K., Kato Y. Four cases of mucous secreting pancreatic cancer. Prog. Dig. Endosc., 1982 20:348–351.
Kloppel G., Luttges J. WHO-classification 2000:Exocrine pancreatic tumors. Verh. Dtsch. Ges. Pathol., 2001 85:219–228.
Tanaka M., Chari S., Adsay V., Fernandez-del Castillo C., Falconi M., Shimizu M., Yamaguchi K., Yamao K., Matsuno S. International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006 6:17–32.
Kokawa A., Kondo H., Gotoda T., Ono H., Saito D., Nakadaira S., Kosuge T., Yoshida S. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001 91:333–338.
Niijima M., Yamaguchi T., Ishihara T., Hara T., Kato K., Kondo F., Saisho H. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 2002 94:1565–1573.
Aoki T., Nagakawa Y., Tsuchida A., Kasuya K., Kitamura K., Inoue K., Ozawa T., Koyanagi Y., Itoi T. Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors. Oncol. Rep. 2002 9:761–765.
Hu P.J., Yu J., Zeng Z.R., Leung W.K., Lin H.L., Tang B.D., Bai A.H., Sung J.J. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004 53:195–200.
Ricchi P., Zarrilli R., Di Palma A., Acquaviva A.M. Nonsteroidal anti-inflammatory drugs in colorectal cancer:from prevention to therapy. Br. J. Cancer 2003 88:803–807.
Adachi T., Tajima Y., Kuroki T., Mishima T., Kitasato A., Fukuda K., Tsutsumi R., Kanematsu T. Bile-reflux into the pancreatic ducts is associated with the development of intraductal papillary carcinoma in hamsters. J. Surg. Res. 2006 136:106–111.
Takahashi M., Pour P., Althoff J., Donnelly T. The pancreas of the Syrian hamster (Mesocricetus auratua). Lab. Anim. Sci. 1977 27:336.
Rinderknecht H., Maset R., Collias K., Carmack C. Pancreatic secretory profiles of protein, digestive, and lysosomal enzymes in Syrian golden hamster. Effect of secretin and cholecysto-kinin. Dig. Dis. Sci. 1983 28:518.
Pour PM. Tomioka T. Tumours of the pancreas. IARC. Sci. Publ. 1996 126:149.
Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994 107:1183–1188.
Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997 57:1276–1280.
Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999 59:198–204.
Patel S., Chiplunkar S. Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer. Indian J. Biochem. Biophys. 2007 44:419–428.
Tsujii M., DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2. Cell 1995 83:493–501.
Tsujii M., Kawano S., DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U. S. A. 1997 94:3336–3340.
Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998 93:705–716.
Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., Sinicrope F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines:growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999 59:4356–4362.
El-Rayes B.F., Ali S., Sarkar F.H., Philip P.A. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 2004 23:1421–1426.
Furukawa F., Nishikawa A., Lee I.S., Kanki K., Umemura T., Okazaki K., Kawamori T., Wakabayashi K., Hirose M. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int. J. Cancer 2003 104:269–273.
Schuller H.M., Zhang L., Weddle D.L., Castonguay A., Walker K., Miller M.S. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J. Cancer Res. Clin. Oncol. 2002 128:525–532.
Crowell P.L., Schmidt C.M., Yip-Schneider M.T., Savage J.J., Hertzler D.A. 2nd, Cummings W.O. Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia 2006 8:437–445.
Matsubayashi H., Infante J.R., Winter J., Klein A.P., Schulick R., Hruban R., Visvanathan K., Goggins M. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol. Ther. 2007 6:1569–1575.
Yip-Schneider M.T., Barnard D.S., Billings S.D., Cheng L., Heilman D.K., Lin A., Marshall S.J., Crowell P.L., Marshall M.S., Sweeney C.J. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000 21:139–146.
Larsson S.C., Giovannucci E., Bergkvist L., Wolk A. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer:a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2006 15:2561–2564.
El-Rayes B.F., Zalupski M.M., Shields A.F., Ferris A.M., Vaishampayan U., Heilbrun L.K., Venkatramanamoorthy R., Adsay V., Philip P.A. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest. New Drugs 2005 23:583–590.
Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 87:803–809.
Maire F., Hammel P., Terris B., Paye F., Scoazec J.Y., Cellier C., Barthet M., O'Toole D., Rufat P., Partensky C., Cuillerier E., Lévy P., Belghiti J., Ruszniewski P. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002 51:717–722.
Sun Y., Tang X.M., Half E., Kuo M.T., Sinicrope F.A. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002 62:6323–6328.
Adachi T, Tajima Y, Kuroki T, Mishima T, Kitasato A, Tsuneoka N, Kanematsu T. Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters. Carcinogenesis 2008 29:830–833.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer
About this chapter
Cite this chapter
Adachi, T. et al. (2009). Chemoprevention of Pancreatic Carcinogenesis. In: Tajima, Y., Kuroki, T., Kanematsu, T. (eds) Hepatobiliary and Pancreatic Carcinogenesis in the Hamster. Springer, Tokyo. https://doi.org/10.1007/978-4-431-87773-8_12
Download citation
DOI: https://doi.org/10.1007/978-4-431-87773-8_12
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-87772-1
Online ISBN: 978-4-431-87773-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)